Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Dr Claire Henry

PositionResearch Fellow
DepartmentDepartment of Obstetrics, Gynaecology and Women's Health (UOW)
QualificationsBSc(Hons I) PhD
Research summaryGynaecological cancers

Research

Claire's research background is in molecular cell biology and genetics of gynaecological cancers, in particular ovarian and endometrial. She is interested in:
  • Mutations in endometrial cancer
  • Obesity related interventions for endometrial cancer
  • Early detection test for ovarian cancer
  • HPV screening programs

Publications

Lu, M., Henry, C. E., Lai, H., Khine, Y. Y., Ford, C. E., & Stenzel, M. H. (2019). A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles. Biomaterials Science. Advance online publication. doi: 10.1039/c8bm01326h

Henry, C. E., Llamosas, E., Daniels, B., Coopes, A., Tang, K., & Ford, C. E. (2018). ROR1 and ROR2 play distinct and opposing roles in endometrial cancer. Gynecologic Oncology, 148(3), 576-584. doi: 10.1016/j.ygyno.2018.01.025

Cortesi, M., Llamosas, E., Henry, C. E., Kumaran, R.-Y. A., Ng, B., Youkhana, J., & Ford, C. E. (2018). I-AbACUS: A reliable software tool for the semi-automatic analysis of invasion and migration transwell assays. Scientific Reports, 8, 3814. doi: 10.1038/s41598-018-22091-5

Henry, C., Hacker, N., & Ford, C. (2017). Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. Oncotarget, 8(68), 112727-112738. doi: 10.18632/oncotarget.22559

Ma, S. S. Q., Henry, C. E., Llamosas, E., Higgins, R., Daniels, B., Hesson, L. B., … Ford, C. E. (2017). Validation of specificity of antibodies for immunohistochemistry: The case of ROR2. Virchows Archiv, 470(1), 99-108. doi: 10.1007/s00428-016-2019-5

Journal - Research Article

Lu, M., Henry, C. E., Lai, H., Khine, Y. Y., Ford, C. E., & Stenzel, M. H. (2019). A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles. Biomaterials Science. Advance online publication. doi: 10.1039/c8bm01326h

Henry, C. E., Llamosas, E., Daniels, B., Coopes, A., Tang, K., & Ford, C. E. (2018). ROR1 and ROR2 play distinct and opposing roles in endometrial cancer. Gynecologic Oncology, 148(3), 576-584. doi: 10.1016/j.ygyno.2018.01.025

Cortesi, M., Llamosas, E., Henry, C. E., Kumaran, R.-Y. A., Ng, B., Youkhana, J., & Ford, C. E. (2018). I-AbACUS: A reliable software tool for the semi-automatic analysis of invasion and migration transwell assays. Scientific Reports, 8, 3814. doi: 10.1038/s41598-018-22091-5

Henry, C., Hacker, N., & Ford, C. (2017). Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis. Oncotarget, 8(68), 112727-112738. doi: 10.18632/oncotarget.22559

Ma, S. S. Q., Henry, C. E., Llamosas, E., Higgins, R., Daniels, B., Hesson, L. B., … Ford, C. E. (2017). Validation of specificity of antibodies for immunohistochemistry: The case of ROR2. Virchows Archiv, 470(1), 99-108. doi: 10.1007/s00428-016-2019-5

Henry, C. E., Emmanuel, C., Lambie, N., Loo, C., Kan, B., Kennedy, C. J., … Ford, C. E. (2017). Distinct patterns of stromal and tumor expression of ROR1 and ROR2 in histological subtypes of epithelial ovarian cancer. Translational Oncology, 10(3), 346-356. doi: 10.1016/j.tranon.2017.01.014

Henry, C. E., Llamosas, E., Djordjevic, A., Hacker, N. F., & Ford, C. E. (2016). Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis, 5, e226. doi: 10.1038/oncsis.2016.32

Henry, C., Llamosas, E., Knipprath-Meszaros, A., Schoetzau, A., Obermann, E., Fuenfschilling, M., … Ford, C. (2015). Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget, 6, 40310-40326. doi: 10.18632/oncotarget.5643

Henry, C., Quadir, A., Hawkins, N. J., Jary, E., Llamosas, E., Kumar, D., … Ford, C. E. (2015). Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. Journal of Cancer Research & Clinical Oncology, 141, 243-254. doi: 10.1007/s00432-014-1824-y

Ford, C. E., Punnia-Moorthy, G., Henry, C. E., Llamosas, E., Nixdorf, S., Olivier, J., … Heinzelmann-Schwarz, V. (2014). The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Gynecologic Oncology, 134(2), 338-345. doi: 10.1016/j.ygyno.2014.06.004

^ Top of page

Journal - Research Other

Ford, C. E., Henry, C., Llamosas, E., Djordjevic, A., & Hacker, N. (2016). Wnt signalling in gynaecological cancers: A future target for personalised medicine? Gynecologic Oncology, 140, 345-351. doi: 10.1016/j.ygyno.2015.09.085

More publications...